Thanks for your reply. I try to understand the changes you made.It works fine for the patient id 4589759 but other ids are not matching .The rule for this analysis are below .The code you posed on 14 th July works 99% correctly only in some cases it is not giving the desired out .I have highlighted those in the red below. LOT1 commences at the start of first core/non-core drug starting from index date. LOT1 comprises all the core/non-core drugs initiated within 21 days of the start of LOT. Three types of regimens may be created: Core drugs only Non-core drugs only Core drugs + Non-core drugs In case of Core only and Core + Non-core LOTs, a date of last use is identified by considering the latest date of last use of any of the core drugs initiated in the 21 days period. In case of Non-core only LOT, a date of last use is identified by considering the latest date of last use of any of the non-core drugs present in LOT1. Currently it is taking only core drugs in initial 21 days which should not be the case any drug indentified irrespective of core or noncore it will be included in the lot but end date would be maximum date of latest use core drug. If LOT1 comprises Core drugs only or Core + Non-core drugs, If any of the core drugs from LOT1 is identified in a period – from end date of most recent core drug to 60 days post date of latest use of a core drug - update the date of latest use accordingly. Again, core drugs are to be identified until 60 days post updated date of last use, and so on. This step is to be repeated until either no core drugs are identified in the given period or a core drug other than the core drugs present in LOT1 is identified. If no core drug is identified from start date of most recent core drug to 60 days post date of latest use of a core drug, LOT1 ends at date of latest use. If a core drug other than the core drugs present in LOT1 is identified from start date of most recent core drug to 60 days post or 21 days period of date of latest use of a core drug, and, one or more core drugs from LOT1 overlap with the newly identified core drug which is not present in LOT1, then LOT1 ends one day prior to the beginning of newly identified core drug. LOT2 begins at the start of newly identified core drug. If any of the overlapping core drugs from LOT1 is further identified any time during LOT2, that drug is included in LOT2. Currently overlapping happens if any core drug from previous lot continues after start of current lot .but we need to check if the core drug continues after start of new lot and it is being start again then this rule should be applied. none of the core drugs from LOT1 overlaps with the new core drug, end LOT1 at latest use of core drugs. LOT2 begins at the start of newly identified core drug. Non-core drugs identified during or after initial 21 days period will not affect duration of LOT1. Currently if a lot comprises core plus non core drugs it is taking the maximum end irrespective of core or non core .But the end date should be the latest use of core drugs in this case. If LOT1 comprises non-core drugs only, If any of the non-core drugs from LOT1 is identified in a period – from end date of most recent non-core drug to 60 days post date of latest use of a non-core drug - update the date of latest use accordingly. Again, non-core drugs from LOT1 are to be identified until 60 days post updated date of last use, and so on. This step is to be repeated until either no non-core drugs from LOT1 are identified in that period or a core drug is identified. If no non-core drug from LOT1 is identified from start date of most recent non-core drug to 60 days post date of latest use of a non-core drug, the regimen ends at date of latest use. If a core drug is identified from start date of most recent non-core drug to 60 days post date of latest use of a non-core drug, and, one or more non-core drugs from LOT1 overlap with the newly identified core drug, then LOT1 ends one day prior to beginning of the newly identified core drug. LOT2 begins at the start of newly identified core drug. none of the non-core drugs from LOT1 overlaps with the newly identified core drug, end LOT1 at latest use of non-core drugs in LOT1. LOT2 begins at the start of newly identified core drug. After the end of an LOT, next LOT can begin, at start of earliest core drug post end of LOT. at start of earliest non-core drug after 60 days post end of LOT given that no core drug precedes it post end of previous LOT. The regimens, start dates and end dates of further LOTs are to be determined in a similar manner. Thanks in advance.Please let me know in case you have any concerns.
... View more